News for Innovent Biologics, Inc. (IVBXF)

SAN FRANCISCO and SUZHOU, China, March 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in its registrational study evaluating IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, as monotherapy versus pembrolizumab (Keytruda®) in patients with unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy. This is IBI363's first pivotal study and a significant milestone for China's innovative immuno-oncology (IO) therapy in addressing the global challenge of treating 'cold tumors.'

PR NewswireSAN FRANCISCO and SUZHOU, China, Feb. 16, 2025 SAN FRANCISCO and SUZHOU, China, Feb. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innoven

SAN FRANCISCO and SUZHOU, China, Feb. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, IBI363, has received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) that has progressed following anti-PD-(L)1 immune checkpoint inhibitor therapy and platinum-based chemotherapy. IBI363 has demonstrated encouraging efficacy and safety across multiple solid tumor types. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI363 mainly in China and the U.S.

Insights into the Fund's Strategic Moves in Q4 2024 Matthews Emerging Markets Small Companies Fund (Trades, Portfolio) recently submitted its N-PORT filing for

SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), jointly announce that China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC). Limertinib is the 14th product in Innovent's commercial portfolio and represents a cutting-edge addition to its strong TKI franchise, offering an innovative precision therapy option to lung cancer patients.

Advancing into new stage of sustainable growth and global innovation

Innovent Biologics Inc (IVBIY), a leading biopharmaceutical company, announced on January 15, 2025, that its drug IBI343 has been granted Breakthrough Therapy D

SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343, a potentially best-in-class TOPO1i anti-CLDN18.2 ADC, as monotherapy for the treatment of CLDN18.2-positive advanced pancreatic ductal adenocarcinoma (PDAC) patients who have progressed after at least one line of prior systematic treatment.

Innovent Biologics Inc (IVBIY), a leading biopharmaceutical company, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled

PR NewswireSAN FRANCISCO and SUZHOU, China, Jan. 5, 2025 SAN FRANCISCO and SUZHOU, China, Jan. 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"

SAN FRANCISCO and SUZHOU, China, Jan. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the company will participate in the 43rd Annual J.P. Morgan Healthcare Conference. During the conference, Dr. De-Chao Michael Yu, the Founder, Chairman and CEO of Innovent, will deliver a company presentation highlighting the organization's business update, strategic priorities and future outlook. Dr. Yu will also participate in a panel discussion session.

Innovent Biologics Inc (IVBIY), a leading biopharmaceutical company, announced on January 2, 2025, that China's National Medical Products Administration (NMPA)

PR NewswireSAN FRANCISCO and SUZHOU, China, Jan. 2, 2025 SAN FRANCISCO and SUZHOU, China, Jan. 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"

On January 1, 2025, Innovent Biologics Inc (IVBIY), a leading biopharmaceutical company, announced a collaboration and exclusive license agreement with Roche to

SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of DOVBLERON ® (taletrectinib adipate capsule), a next-generation ROS1 tyrosine kinase inhibitor (TKI), for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with ROS1 TKIs. DOVBLERON® marks the 13th addition to Innovent's commercial portfolio, representing an innovative precision therapy expected to benefit more lung cancer patients alongside our strong TKI franchise.

6 June 2024Worldwide Healthcare Trust PLC ...

Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)

Revolution is pioneering a unique precision-based approach to developing oncology drugs that target the RAS pathway. Read why I'm neutral on RVMD stock.

The growing frequency of chronic diseases such as asthma, arthritis, chronic obstructive pulmonary disease (COPD), and others is driving up demand for...